



OraSure Technologies Appoints Carter H. Eckert to Board of Directors

December 7, 2001

BETHLEHEM, Pa., Dec 7, 2001 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the appointment of Carter H. Eckert to the Company's Board of Directors.

This appointment increases the size of OraSure's Board to eight members.

Mr. Eckert has enjoyed a distinguished career in the pharmaceutical industry spanning four decades. Most recently, Mr. Eckert was President and Chief Executive Officer of Knoll Pharmaceutical Company and President of the Americas for Knoll's parent company, BASF Pharma.

In addition, he was a member of BASF Pharma's Global Pharmaceutical Board responsible for global therapeutic franchises and corporate transactions. Prior to joining BASF Pharma in 1995, Mr. Eckert was President and Chief Executive Officer of Boots Pharmaceuticals, Inc. in Lincolnshire, IL, where he was responsible for North American operations.

Mr. Eckert joined Boots in 1985 as Executive Vice President and Chief Operating Officer after more than a decade at Baxter Travenol Laboratories in Deerfield, IL, where he served in a number of positions including President of Baxter's Flint Division.

"I am pleased to welcome Carter to the OraSure Board and look forward to his contributions during this exciting phase of the Company's growth," commented Robert D. Thompson, Chief Executive Officer for the Company. "Carter's significant operating and strategic planning experience represents a significant addition to our Board."

Mr. Eckert received his B.S. in Chemical Engineering from the Illinois Institute of Technology and his MBA from Northwestern University. Mr. Eckert is a member of the Aethena Group, LLC advisory board and a Trustee of Caldwell College.

About OraSure Technologies

OraSure Technologies, Inc. develops, manufactures and markets medical devices and diagnostic products for use by public- and private-sector clients, clinical laboratories, physicians' offices and workplace testing.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the Company supplies oral fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

CONTACT: OraSure Technologies, Inc., Bethlehem
Ronald H. Spair, 610/882-1820
Investorinfo@orasure.com